Inhibition of angiogenesis by HC·HA, a complex of hyaluronan and the heavy chain of inter-α-Inhibitor, purified from human amniotic membrane

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 5, 2011, Pages 2669-2678

  Shay, Elizabeth ^a   He, Hua ^a   Sakurai, Shunsuke ^a   Tseng, Scheffer C G ^a,b  

^a TISSUETECH INC   (United States)

^b OCULAR SURFACE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACTIN; AMINIOTIC MEMBRANE EXTRACT; BROXURIDINE; CARBOHYDRATE DERIVATIVE; HERMES ANTIGEN; HYALURONIC ACID; HYALURONIC ACID HEAVY CHAIN OF INTER ALPHA INHIBITOR; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN DERIVATIVE; SOMATOMEDIN BINDING PROTEIN 1; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TISSUE EXTRACT; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMNION; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ADHESION; CELL ASSAY; CELL DEATH; CELL DIFFERENTIATION; CELL LABELING; CELL MIGRATION; CELL PROLIFERATION; CELL SHAPE; CELL SPREADING; CELL VIABILITY; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAVY CHAIN; HUMAN; HUMAN CELL; IC 50; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PURIFICATION; TISSUE TRANSPLANTATION;

ALPHA-GLOBULINS; AMNION; ANGIOGENESIS INHIBITORS; ANIMALS; CELL ADHESION; CELL DEATH; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHICK EMBRYO; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYALURONIC ACID; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 79955998921     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5888     Document Type: Article

References (44)

1. Kruse FE, Joussen AM, Rohrschneider K, et al. Cryopreserved human amniotic membrane for ocular surface reconstruction. Graefe's Arch Clin Exp Ophthalmol. 2000;238:68-75.
2. Kim JC, Tseng SCG. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. Korean J Ophthalmol. 1995;9: 32-46.
3. Tseng SCG, Prabhasawat P, Barton K, Gray T, Meller D. Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency. Arch Ophthalmol. 1998;116:431-441.
4. Tsubota K, Satake Y, Kaido M, et al. Treatment of severe ocular surface disorders with corneal epithelial stem-cell transplantation. N Engl J Med. 1999;340:1697-1703.
5. Tsai RJF, Li L-M, Chen J-K. Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells. N Engl J Med. 2000;343:86-93.
6. Sippel KC, Ma JJK, Foster CS. Amniotic membrane surgery. Curr Opin Ophthalmol. 2001;12:269-281.
7. Tseng SCG. Amniotic membrane transplantation for ocular surface reconstruction. Biosci Rep. 2002;21:481-489.
8. Dua HS, Gomes JA, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. Surv Ophthalmol. 2004;49:51-77.
9. Bouchard CS, John T. Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. Ocul Surface. 2004;2:201-211.
10. Tseng SCG, Espana EM, Kawakita T, et al. How does amniotic membrane work? Ocul Surface. 2004;2:177-187.
11. Jiang A, Li C, Gao Y, et al. In vivo and in vitro inhibitory effect of amniotic extraction on neovascularization. Cornea. 2006;25: S36-S40.
12. He H, Li W, Tseng DY, et al. Biochemical characterization and function of complexes formed by hyaluronan and the heavy chains of inter-α-inhibitor (HC·HA) purified from extracts of human amniotic membrane. J Biol Chem. 2009;284:20136-20146.
13. Fulop C, Szanto S, Mukhopadhyay D, et al. Impaired cumulus mucification and female sterility in tumor necrosis factor-induced protein-6 deficient mice. Development. 2003;130:2253-2261.
14. Jessen TE, Odum L. Role of tumour necrosis factor stimulated gene 6 (TSG-6) in the coupling of inter-alpha-trypsin inhibitor to hyaluronan in human follicular fluid. Reproduction. 2003;125:27-31.
15. Rugg MS, Willis AC, Mukhopadhyay D, et al. Characterization of complexes formed between TSG-6 and inter-alpha-inhibitor that act as intermediates in the covalent transfer of heavy chains onto hyaluronan. J Biol Chem. 2005;280:25674-25686.
16. Li W, He H, Kawakita T, Espana EM, Tseng SCG. Amniotic membrane induces apoptosis of interferon-gamma activated macrophages in vitro. Exp Eye Res. 2006;82:282-292.
17. He H, Li W, Chen SY, et al. Suppression of activation and induction of apoptosis in RAW264.7 cells by amniotic membrane extract. Invest Ophthalmol Vis Sci. 2008;49:4468-4475.
18. Kawakita T, Espana EM, He H, et al. Keratocan expression of murine keratocytes is maintained on amniotic membrane by downregulating TGF-beta signaling. J Biol Chem. 2005;280:27085-27092.
19. Kawakita T, Espana EM, He H, et al. Preservation and expansion of the primate keratocyte phenotype by downregulating TGF-beta signaling in a low-calcium, serum-free medium. Invest Ophthalmol Vis Sci. 2006;47:1918-1927.
20. Ochsner SA, Day AJ, Rugg MS, Breyer RM, Gomer RH, Richards JS. Disrupted function of tumor necrosis factor-alpha-stimulated gene 6 blocks cumulus cell-oocyte complex expansion. Endocrinology. 2003;144:4376-4384.
21. McKee CM, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages: the role of HA size and CD44. J Clin Invest. 1996; 98:2403-2413.
22. Rooney P, Wang M, Kumar P, Kumar S. Angiogenic oligosaccharides of hyaluronan enhance the production of collagens by endothelial cells. J Cell Sci. 1993;105(pt 1):213-218.
23. Morrison H, Sherman LS, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001;15:968-980.
24. Slevin M, Krupinski J, Gaffney J, et al. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol. 2007;26:58-68.
25. Han YS, Lee JE, Jung JW, Lee JS. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247:541-548.
26. Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemiainduced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci U S A. 2001;98: 2593-2597.
27. Shao C, Sima J, Zhang SX, et al. Suppression of corneal neovascularization by PEDF release from human amniotic membranes. Invest Ophthalmol Vis Sci. 2004;45:1758-1762.
28. Hao Y, Ma DH-K, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea. 2000;19:348-352.
29. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cellbinding domain of fibronectin. Am J Pathol. 2000;156:1345-1362.
30. Schwartz MA, Assoian RK. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci. 2001;114:2553-2560.
31. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA. Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol. 2003;162:933-943.
32. Wijelath ES, Rahman S, Namekata M, et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res. 2006;99:853-860.
33. Kobayashi N, Kabuyama Y, Sasaki S, Kato K, Homma Y. Suppression of corneal neovascularization by culture supernatant of human amniotic cells. Cornea. 2002;21:62-67.
34. Ma DH, Yao JY, Yeh LK, et al. In vitro antiangiogenic activity in ex vivo expanded human limbocorneal epithelial cells cultivated on human amniotic membrane. Invest Ophthalmol Vis Sci. 2004;45: 2586-2595.
35. Ben LN, Seurin D, Le BY, et al. Insulin-like growth factor binding protein (IGFBP-1) involvement in intrauterine growth retardation: study on IGFBP-1 overexpressing transgenic mice. Endocrinology. 2006;147:4730-4737.
36. Watson CS, Bialek P, Anzo M, Khosravi J, Yee SP, Han VK. Elevated circulating insulin-like growth factor binding protein-1 is sufficient to cause fetal growth restriction. Endocrinology. 2006;147:1175-1186.
37. Hagedorn M, Zilberberg L, Lozano RM, et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J. 2001;15:550-552.
38. Jouan V, Canron X, Alemany M, et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood. 1999;94:984-993.
39. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990;247:77-79.
40. Rooney P, Kumar S, Ponting J, Wang M. The role of hyaluronan in tumour neovascularization (review). Int J Cancer. 1995;60:632-636.
41. West DC, Fan PD. Hyaluronan oligosaccharides promote wound repair. In: Kohn EC, Fan PD, eds. The New Angiotherapy. Totowa, NJ: Humana Press; 2002:177-186.
42. Feinberg RN, Beebe DC. Hyaluronate in vasculogenesis. Science. 1983;220:1177-1179.
43. West DC, Kumar S. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res. 1989;183:179.
44. Qian Y, Luo J, Leonard SS, et al. Hydrogen peroxide formation and actin filament reorganization by Cdc42 are essential for ethanolinduced in vitro angiogenesis. J Biol Chem. 2003;278:16189-16197.